Targeted Cytotoxic Composition for Lens Fibrotic Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are ineffective in blocking the development of lens fibrotic diseases such as posterior capsule opacification (PCO) and anterior subcapsular cataract, which result from myofibroblasts causing vision loss after cataract surgery, with no established method to inhibit these conditions.
Innovation Solution
Administering a composition comprising skeletal muscle stem cell targeting molecules conjugated with cytotoxic molecules and a pharmaceutically acceptable carrier directly to the lens or surrounding tissue to inhibit or treat lens fibrotic diseases by reducing or eliminating skeletal muscle stem cells, which are responsible for myofibroblast formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to treat lens fibrotic diseases, then general treatment approaches are applied, but they are ineffective in blocking the development of lens fibrotic diseases
Solution Approach 1:
The patent uses a targeting molecule as an intermediary that specifically binds to skeletal muscle stem cells in the lens. This targeting molecule conjugated to a cytotoxic agent delivers the therapeutic effect selectively to the pathogenic cells while sparing normal lens epithelial cells, thereby resolving the contradiction between effective treatment and cellular specificity.
2Reliability
If cytotoxic agents are administered to eliminate skeletal muscle stem cells, then myofibroblast formation is reduced, but specificity of targeting is required to avoid damaging normal lens cells
Solution Approach 1:
The patent applies local quality by creating a conjugate where the cytotoxic agent is directed only to skeletal muscle stem cells through specific binding of the targeting molecule to cell surface markers on these cells. This localized delivery ensures that normal lens epithelial cells are not exposed to or damaged by the cytotoxic agent, resolving the contradiction between eliminating pathogenic cells and protecting normal tissue.
3Reliability
If no specific treatment is applied, then lens fibrotic diseases develop unchecked, but conventional treatments lack the precision to target the specific cell population responsible
Solution Approach 1:
The patent employs a composite material consisting of a targeting molecule conjugated to a cytotoxic agent. This composite structure combines the specific binding capability of the targeting molecule with the cell-killing activity of the cytotoxic agent, enabling precise and effective treatment of lens fibrotic diseases while managing the complexity through a well-defined molecular conjugate.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively suppresses the expression of α-smooth muscle actin and reduces myofibroblast formation, thereby inhibiting or treating lens fibrotic diseases like PCO and cataracts by specifically targeting and eliminating the causative skeletal muscle stem cells.
Implementation Method 1
at least one cytotoxic molecule conjugated with at least one skeletal muscle stem cell targeting molecule
Data Source
AI summary
Compositions and methods for treating fibrotic diseases are provided.